Headache as the most  prevalent post-vaccination adverse event after Covid-19 vaccination

Francisco Ricardo Nascimento Freitas; Edmar José Fortes  Júnior; Débora Joyce Nascimento Freitas; Samara Menali Pereira Caproni; Daniela França de Barros; Raimundo Pereira da Silva Neto

doi:10.48208/HeadacheMed.2024.3

Authors

Francisco Ricardo Nascimento Freitas Universidade Federal do Delta do Parnaíba https://orcid.org/0000-0003-2655-619X
Edmar José Fortes Júnior Instituto de Educação Superior do Vale do Parnaíba https://orcid.org/0000-0002-0114-9937
Débora Joyce Nascimento Freitas Universidade Federal do Ceará https://orcid.org/0000-0002-9052-1365
Samara Menali Pereira Caproni Universidade José do Rosário Vellano https://orcid.org/0009-0003-8755-2237
Daniela França de Barros Universidade Federal do Delta do Parnaíba https://orcid.org/0000-0002-3667-7510
Raimundo Pereira da Silva Neto Universidade Federal do Delta do Parnaíba https://orcid.org/0000-0002-2343-9679

DOI:

https://doi.org/10.48208/HeadacheMed.2024.3

Keywords:

Adverse Effect, Headache, COVID-19 Vaccines

Abstract

Context: In 2020, the first vaccines were approved, according to the WHO. However,
speculations have arisen regarding its efficacy and post-vaccination adverse events (AEFI).
Objective: To evaluate the prevalence of headache as AEFI from the SARSCoV-2 vaccine in Piauí,
Brazil.
Methods: This is a quantitative, observational, cross-sectional and prevalence study.
The data were provided by the Post-Vaccination Adverse Events Information System (SI-AEFV),
of cases reported in the period from January to September 2021.
The data were analyzed and the research was approved by the Research Ethics Committee of the UFPI.
Results: 2,008 cases were analyzed. Headache was reported in 752 cases (27.99%) as AEFI after vaccination
against SARS-CoV-2. In most cases, the patients were from Teresina (67.62%), of mixed race/ethnicity (52.67%),
female (79.00%) and the majority were not healthcare professionals (54. 27%). The most common age of patients,
with the original data, was 33 years old. After correcting the data, the most common age was 28 years old.
The majority of these cases were not serious (96.44%) and the majority of cases were associated with the first dose of the Covid-19-Covishield-Oxford/AstraZeneca vaccine (43.18%). Conclusion: Thus, it is concluded from the partial analysis of the results that headache is the most common adverse event after vaccination against SARS-CoV-2. The profile of patients with the most notifications was mixed-race women aged between 30 and 40 years who received the first dose of the Covid-19-Covishield-Oxford/AstraZeneca vaccine. Regarding the severity of the events, the vast majority were considered non-serious and no deaths were mentioned, demonstrating the safety of immunobiologicals.

Downloads

Download data is not yet available.

References

Ciotti M, Ciccozzi M, Terrinoni A, Jiang W-C, Wang C-B, Bernardini S. The COVID-19 pandemic. Critical

Reviews in Clinical Laboratory Sciences. 2020;57(6):365-88.Doi 10.1080/10408363.2020.1783198 DOI: https://doi.org/10.1080/10408363.2020.1783198

Lima EJF, Almeida AM, Kfouri RÁ. Vaccines for COVID-19 - state of the art. Revista Brasileira de Saúde Materno Infantil. 2021;21(suppl 1):13-9.Doi 10.1590/1806-9304202100s100002 DOI: https://doi.org/10.1590/1806-9304202100s100002

Oliveira PMN, Lignani LK, Conceição DA, Farias PMCM, Takey PRG, Maia MLS, et al. O panorama

da vigilância de eventos adversos pós-vacinação ao fim da década de 2010: importância, ferramentas e desafios. Cadernos de Saúde Pública. 2020;36(suppl 2).Doi 10.1590/0102-311x00182019 DOI: https://doi.org/10.1590/0102-311x00182019

Haseeb AA, Solyman O, Abushanab MM, Abo Obaia AS, Elhusseiny AM. Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective. Vaccines. 2022;10(2).Doi 10.3390/vaccines10020342 DOI: https://doi.org/10.3390/vaccines10020342

Silva RB, Silva TPR, Sato APS, Lana FCF, Gusmão JD, Souza JFA, et al. Eventos adversos pós-vacinação contra o SARS-CoV-2 (covid-19) no estado de Minas Gerais. Revista de Saúde Pública. 2021;55. Doi 10.11606/s1518-8787.2021055003734 DOI: https://doi.org/10.11606/s1518-8787.2021055003734

Pacheco F, Domingues C, Maranhão A, Carvalho S, Teixeira A, Braz R, et al. Análise do Sistema de Informação da Vigilância de Eventos Adversos Pós-Vacinação no Brasil, 2014 a 2016. Revista Panamericana de Salud Pública. 2018:1-8.Doi 10.26633/rpsp.2018.12 DOI: https://doi.org/10.26633/RPSP.2018.12

Sousa VD, Driessnack M, Mendes IAC. An overview of research designs relevant to nursing: Part 1: quantitative research designs. Revista LatinoAmericana de Enfermagem. 2007;15(3):502-7.Doi 10.1590/s0104-11692007000300022 DOI: https://doi.org/10.1590/S0104-11692007000300022

Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2

infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective

observational study. The Lancet Infectious Diseases. 2021;21(7):939-49.Doi 10.1016/s1473- 3099(21)00224-3

Sbors G, Peder LD. Eventos Adversos Pós-Vacinação Contra a Covid-19 Em Lindoeste, No Paraná. RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218. 2022;3(10).Doi 10.47820/recima21. v3i10.2028 DOI: https://doi.org/10.47820/recima21.v3i10.2028

Recuero R, Volcan T, Jorge FC. Os efeitos da pandemia de covid-19 no discurso antivacinação infantil no Facebook. Revista Eletrônica de Comunicação, Informação & Inovação em Saúde. 2022;16(4):859-82.Doi 10.29397/reciis.v16i4.3404 DOI: https://doi.org/10.29397/reciis.v16i4.3404

Instituto Brasileiro de Geografia e Estatística - IBGE. Cidades e Estados. 2022. Available:<https://www.ibge.gov.br/cidades-e-estados/pi.html>.

World Health Organization - WHO. Monitoring vaccination against COVID-19: Considerations on the collection and use of vaccination data. 2021. Available: <https://www.who.int/publications/i/item/monitoring-covid-19- vaccination-interim-guidance>.

Silva LPD, Soccol EB, Reis FLD, et al. Eventos adversos pós-vacinação covid-19. Anais da Semana da Enfermagem, 2022. Available in: https://lume.ufrgs.br/handle/10183/250316

Brasil. Ministério da Saúde. Conselho Nacional de Saúde. COVID-19 Vacinação. Brasilia: Ministério da Saúde, 2022. Available in: https://conselho.saude.gov.br/vacinometro

Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária (ANVISA). Relatório - Bases

Técnicas Para Decisão do Uso Emergencial, em Caráter Experimental de Vacinas Contra a COVID-19. Brasilia: Ministério da Saúde; 2021. Available in: https://www.gov.br/anvisa/pt-br/assuntos/noticias anvisa/2021/confira-materiaisda-reuniao-extraordinaria-da-dicol/relatoriobases-tecnicas-para-decisao-do-uso-emergencialfinal-4-1.pdf

Nunes L. Panorama da cobertura vacinal no Brasil. São Paulo: Instituto de Estudos para Políticas

de Saúde, 2021. Relatório. Available in: https://ieps.org.br/wp-content/uploads/2021/05/Panorama_

IEPS_01.pdf.

Dandara L. Programa Nacional de Imunizações é um marco histórico na saúde pública brasileira.

Portal Fiocruz, Rio de Janeiro, 9 jun. 2022. Available in: https://portal.fiocruz.br/noticia/programa-nacionalde-imunizacoes-e-um-marcohistorico-na-saude-publica-brasileira.

Fioravanti C. Erradicação da varíola há 50 anos no Brasil adotou técnicas usadas até hoje. Revista Pesquisa Fapesp, 2021. Available in: https://revistapesquisa.fapesp.br/os-caminhos-abertospela-primeira-vacina/.

Headache as the most prevalent post-vaccination adverse event after Covid-19 vaccination

Authors

DOI:

Keywords:

Abstract

Downloads

References

Downloads

Published

How to Cite

Issue

Section

License

Most read articles by the same author(s)

Language

Make a Submission

Style